HOME >> MEDICINE >> NEWS
ICAAC highlight: MAC prophylaxis can be safely discontinued in HIV-infected,,patients who respond to HAART

Prophylactic treatment for the opportunistic infection known as MAC (Mycobacterium avium complex) can be safely discontinued in most HIV-infected patients whose CD4+ T-cell levels show sustained increases in response to potent antiretroviral therapy, according to interim results of a study supported by the National Institute of Allergy and Infectious Diseases (NIAID). Study Chair Judith Currier, M.D., associate professor of medicine at the University of California, Los Angeles, will present the findings on Monday, Sept. 27, during a late-breaker session at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy being held in San Francisco.

Before highly active antiretroviral therapy (HAART) became available in the mid-1990s, MAC was one of the most common serious opportunistic infections associated with HIV infection. It usually caused widespread infection in multiple organs, leading to debilitating symptoms and significantly decreased chances of survival.

Nearly two years ago, the AIDS Clinical Trials Group (ACTG), a network of HIV research clinicians supported by NIAID, launched a multicenter study known as ACTG 362. The purpose of the study was to determine if an adequate response to HAART--defined as a sustained rise in CD4+ T cells from less than 50 to more than 100 per cubic millimeter (mm3) of blood--protected HIV-infected individuals from developing MAC infection.

A total of 643 patients enrolled in the two-arm, placebo-controlled study. By random assignment, 321 received placebo and 322 received once-weekly, 1200-milligram (mg) doses of azithromycin, supplied by the drug manufacturer, Pfizer. Azithromycin is one of the standard drug regimens given patients to prevent MAC. Patients whose CD4+ T-cell counts later fell below 50 were switched to open-label azithromycin.

An interim analysis of the data accrued through the end of July 1999 showed that after a median follow-up of 56 weeks, there were no signif
'"/>

Contact: Laurie K. Doepel
ldoepel@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
27-Sep-1999


Page: 1 2

Related medicine news :

1. Pharmacokinetic data presented at ICAAC on investigational HIV protease inhibitor 433908 (908)
2. Targeted antiviral prophylaxis of flu case contacts could successfully contain pandemic influenza
3. Nursing mothers having surgery -- How long a wait to breastfeed safely?
4. Type 1 diabetes safely arrested with short-term use of new drug
5. Study: ER docs can give stroke clot-busters safely, but patients need to get to ER faster
6. Common heart failure drugs can be safely used at higher, more effective doses, study says
7. New hand-held information system for emergency responders
8. Medical molecules designed to respond to visible light that can penetrate tissue
9. Florida Department of Citrus responds to URMCs release on grapefruit-drug interactions
10. Cell marker identifies patients who are more likely to respond to taxol
11. More than half of relapsed CLL patients respond to two biologics with chemotherapy

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/28/2020)... ... May 28, 2020 , ... Today the National Kidney ... Donors can now be reimbursed for lost wages and travel/lodging costs for any ... Shield protections include lost wage reimbursement for donation, travel & lodging reimbursement for ...
(Date:5/27/2020)... (PRWEB) , ... May 27, 2020 , ... ... announces that it is now manufacturing face shields to be used as ... that causes COVID-19. These face shields are single use, made to be worn ...
(Date:5/27/2020)... ... May 27, 2020 , ... ... practices in the United States, has aligned with the Strategic Radiology (SR) coalition ... of Virginia to join the SR coalition, which has 28 member practices in ...
(Date:5/26/2020)... ... May 26, 2020 , ... New research ... the brain causing post infectious encephalitis. The work was conducted to determine ... (Pediatric Acute-onset Neuropsychiatric Syndrome) could adversely attack the central nervous system and ...
(Date:5/26/2020)... ... May 26, 2020 , ... Today TRC Companies (ā€œ TRC ... online tool that will help business owners and leaders assess whether their organizations are ... This latest offering from TRC is intended to assist business leaders evaluate their readiness ...
Breaking Medicine News(10 mins):
(Date:5/25/2020)... Fla. (PRWEB) , ... May 25, 2020 , ... ... OMMU ), continues its statewide expansion with a three-day, Memorial Day Opening, starting Monday ... in Bonita Springs. , During the opening, staggered over three-days for crowd mitigation, all ...
(Date:5/21/2020)... ... May 21, 2020 , ... After ... began implementing telehealth solutions in order to continue seeing patients despite lockdowns and ... the place for virtual care and complete healthcare communications, conducted online by The ...
(Date:5/21/2020)... ... 2020 , ... MedVet, a leader in emergency and specialty veterinary healthcare, is ... Dr., Mountain View, CA in June 2020. MedVet Mountain View joins existing MedVet hospitals ... Silicon Valley and broader Santa Clara County areas. Concurrent to opening MedVet Mountain View, ...
Breaking Medicine Technology:
Cached News: